top of page
Search
  • Writer's pictureA2A Pharma
    • May 16, 2019
    • 1 min read

A2A Panelist

Updated: Feb 7, 2020

A2A Founder & CEO Edward Painter was a panelist at BIO Investor forum panel entitled "Applying artificial intelligence to improve therapy development today"


LEARN MORE

46 views0 comments

Recent Posts

See All

Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, announced the closing of

bottom of page